New Oncology Drugs/Indications Approved by the FDA.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 51
- Publication type:
- Article
Works matching IS 21641153 AND DT 2021 AND VI 11 AND IP 1
Results: 13
1
2
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 50
- Publication type:
- Article
3
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 49
- Publication type:
- Article
4
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 48
- Publication type:
- Article
5
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 47
- Publication type:
- Article
6
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 46
- Publication type:
- Article
7
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 45
- Publication type:
- Article
8
Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 37
- By:
- Publication type:
- Article
9
Evaluation of Infusion-Related and Hypersensitivity Reactions to Chemotherapy Over a Decade at a Community Cancer Center.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 30
- By:
- Publication type:
- Article
10
Electrolyte Abnormalities and the Associated Risk for Atrial Fibrillation After Autologous Hematopoietic Stem-Cell Transplant.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 24
- By:
- Publication type:
- Article
11
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 22
- By:
- Publication type:
- Article
12
Optimizing Response to Enasidenib with Dose Escalation in Relapsed or Refractory Acute Myeloid Leukemia.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 15
- By:
- Publication type:
- Article
13
Optimizing Daratumumab Infusion: Assessing the Safety and Feasibility of Omitting Preinfusion Medications and Decreasing Infusion Time.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 1, p. 10
- By:
- Publication type:
- Article